A resolution designating the first full week in May as "Tardive Dyskinesia Awareness Week".
- Bill Number
- S.Res. 477
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-10-30: Referred to the Committee on the Judiciary. (text: CR S7851-7852)
- Last Updated
- 2025-12-02T16:33:17Z
AI-Generated Summary
Purpose
This Senate resolution aims to raise public awareness about tardive dyskinesia (TD), a movement disorder that can result from long-term use of antipsychotic medications prescribed for mental health conditions like bipolar disorder, major depressive disorder, and schizophrenia. It designates a specific week each year to promote education on TD risks, symptoms, early detection, and screening to improve patient outcomes and quality of life.
Key Provisions
- Designation of Awareness Week: The Senate officially designates the first full week in May as "Tardive Dyskinesia Awareness Week."
- Support for Awareness Efforts:
- Emphasizes the importance of early detection and intervention for individuals with mental health conditions or those prescribed antipsychotics.
- Encourages education on TD causes (linked to prolonged antipsychotic use), symptoms (uncontrollable, repetitive movements of the face, body, or limbs), and the need for routine screening.
- Background Rationale: Highlights rising antipsychotic prescriptions, higher TD risks for certain groups (e.g., people over 55, Black individuals, women, those with mood/substance use disorders, intellectual disabilities, or brain injuries), and the fact that about 60% of the estimated 800,000 U.S. adults with TD are undiagnosed. It notes American Psychiatric Association guidelines recommending regular TD screening and the availability of FDA-approved treatments for symptom management.
Significant Changes to Existing Law
This is a non-binding Senate resolution, so it introduces no enforceable changes to existing laws or regulations. It serves as a symbolic expression of congressional support rather than creating new legal requirements.
Potential Impacts
- On Citizens: Could increase awareness and encourage more people taking antipsychotics to seek screenings from healthcare providers, potentially leading to earlier diagnosis, better symptom management, and reduced stigma for the 800,000+ affected adults. This may improve physical, social, and emotional well-being, especially for high-risk groups.
- On Government Agencies: Minimal direct impact; it may indirectly support public health initiatives by the Food and Drug Administration (FDA) and health organizations, but no new funding or mandates are imposed.
- On International Relations: No impact, as this is a domestic awareness measure focused on U.S. public health.
Main Stakeholders Affected
- Patients and At-Risk Individuals: People with serious mental illnesses treated with antipsychotics, particularly high-risk groups like older adults, women, Black individuals, and those with co-occurring disorders or disabilities.
- Healthcare Providers: Psychiatrists, primary care doctors, and other professionals who prescribe antipsychotics and are encouraged to follow screening guidelines.
- Caregivers and Families: Those supporting patients, who benefit from awareness to advocate for better care.
- Health Organizations: Groups like the American Psychiatric Association, which align with the resolution's emphasis on clinical best practices.
Notable Legal, Constitutional, or Political Implications
- Legal: As a simple resolution, it has no force of law and does not amend statutes or require compliance; it's purely advisory to promote voluntary awareness.
- Constitutional: No implications, as it falls within Congress's broad authority to pass resolutions on public health matters without infringing on individual rights.
- Political: Represents bipartisan support (introduced by Senators Mullin and Padilla) for mental health advocacy, potentially influencing future legislation on psychiatric care or drug side effects, but it carries no budgetary or regulatory weight.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-10-30: Referred to the Committee on the Judiciary. (text: CR S7851-7852)
- 2025-10-30: Introduced in Senate
Bill Versions
- Designating the first full week in May as Tardive Dyskinesia Awareness Week. — issued 2025-10-30 — PDF (3 pages)